Search the Newsreel

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Axsome Therapeutics reported Q2 revenues of US$218m, meeting expectations, but statutory losses per share were higher at US$0.99. Analysts reconfirmed revenue forecasts for 2026 at US$972.9m, a 25% increase, but expanded per-share loss expectations to US$2.62. Despite the mixed outlook, the consensus price target …

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of "Moderate Buy" by Brokerages

Axsome Therapeutics (NASDAQ:AXSM) has received a consensus "Moderate Buy" rating from 22 brokerages, with an average 12-month price target of $267.60, significantly above its current trading price of $214.66. This comes despite the company missing its latest quarterly earnings expectations, reporting a wider loss …

UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating

UBS has increased its price target for Axsome Therapeutics (NASDAQ: AXSM) to $280 from $259, while maintaining a Buy rating on the stock. This adjustment reflects UBS's continued positive outlook on the biopharmaceutical company. Separately, Mizuho also adjusted its price target for Axsome Therapeutics …

Quantinno Capital Management LP Acquires 5,019 Shares of Axsome Therapeutics, Inc. $AXSM

Quantinno Capital Management LP increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by 77.5% in the first quarter, purchasing an additional 5,019 shares and bringing its total holdings to 11,497 shares valued at $1.94 million. Despite revenue growth driven by Auvelity sales, Axsome Therapeutics missed …

Axsome Therapeutics (AXSM) Stock Faces Revenue Momentum And Lingering Losses

Axsome Therapeutics (AXSM) reported Q2 revenue of US$218.4m, driven by its neurology brands, but also posted a net loss of US$51.3m, causing a slight stock pullback. While revenue growth is strong, particularly from AUVELITY, concerns remain about profitability due to high gross-to-net discounts, rising …

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

Axsome Therapeutics AXSM incurred a loss of 99 cents per share in the second quarter of 2026, which was in line with the Zacks Consensus Estimate. The company had reported a loss of 97 cents per share in the year-ago quarter. Axsome's total revenues …

Axsome Therapeutics (AXSM) Shares Just Climbed, So What Is Driving Attention Now?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Axsome Therapeutics earnings event and why it matters Axsome Therapeutics (AXSM) just reported second quarter 2026 results, with revenue of US$218.38 million and a net …

Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition (AXSM)

AXSOME THERAPEUTICS, INC. : MORGAN STANLEY RAISES TARGET PRICE TO $251 FROM $242

Morgan Stanley has increased its target price for Axsome Therapeutics, Inc. (AXSM) to $251 from $242. This update reflects an analyst's revised valuation for the company. The article, sourced from Reuters, provides this key financial adjustment.

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $268.00

Does Axsome Therapeutics (AXSM) Look Fairly Valued At This Price?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Axsome Therapeutics has delivered a very large 5 year return while the current valuation …

Faster Revenue Growth With Wider Losses Might Change The Case For Investing In Axsome (AXSM)

Axsome Therapeutics, Inc. reported increased revenue in Q2 2026 but also widened net losses, driven by expanding its CNS portfolio and commercialization efforts. While revenue growth is strong, the growing net loss and cash burn raise concerns for investors regarding the company's ability to …

Axsome Therapeutics (NASDAQ: AXSM) grows Q2 2026 revenue but remains unprofitable

Axsome signals 1 NDA per year through 2030 as AXS-12 targets May 1, 2027 PDUFA

Earnings Call Insights: Axsome Therapeutics (AXSM) Q2 2026 MANAGEMENT VIEW * "The second quarter was highly productive for Axsome as we grew our commercial business robustly and made important regulatory and clinical progress across our innovative neuroscience pipeline," said "Founder, Chairman, CEO & President …

Axsome Therapeutics shares gain 2% as strong sales growth offsets Q2 miss

Axsome Therapeutics (NASDAQ:AXSM) shares rose 2.09% in pre-market trading despite missing Q2 earnings and revenue expectations, as investors focused on robust underlying product growth. The company reported a wider loss of $0.99 per share and revenue of $218.4 million, but sales surged 46% year-over-year, …

Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say

Axsome Therapeutics Q2 Earnings Call Highlights

Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates

Axsome Therapeutics (NASDAQ:AXSM) Issues Quarterly Earnings Results

Axsome Therapeutics Inc earnings missed by $0.14, revenue fell short of estimates

Axsome Therapeutics Inc (NASDAQ: AXSM) reported its second-quarter earnings, missing analyst estimates for both EPS and revenue. The company posted an EPS of $-0.99 against an estimated $-0.85, and revenue of $218.37M fell short of the $221.92M consensus. Despite the recent miss, the stock …

Earnings Flash (AXSM) Axsome Therapeutics, Inc. Reports Q2 Revenue $218.4M, vs. FactSet Est of $221.1M

Axsome Therapeutics, Inc. (AXSM) reported its Q2 revenue at $218.4 million, falling short of the FactSet estimate of $221.1 million. The company's stock was trading at $219.19 USD with a 3.03% change on August 10, 2026. This earnings flash was published at 07:21 am …

Axsome Reports 126% More AUVELITY Starts Among 65+ Patients in 8 Weeks

Axsome Therapeutics announced strong financial results for Q2 2026, with total net product revenue increasing 46% year-over-year to $218.4 million, driven by significant growth in sales of AUVELITY, SUNOSI, and SYMBRAVO. The company reported a net loss of $51.3 million but indicated that current …

Axsome Therapeutics (NASDAQ: AXSM) Q2 revenue jumps 46% as CNS pipeline advances

Axsome Therapeutics reported strong Q2 2026 revenue growth, with total net product revenue increasing 46% year-over-year to $218.4 million, driven by AUVELITY, SUNOSI, and SYMBRAVO sales. Despite this growth, the company posted a net loss of $51.3 million due to higher SG&A expenses from …

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Axsome Therapeutics reported strong second-quarter 2026 financial results, with total net product revenue reaching $218.4 million, a 46% year-over-year increase, driven by significant growth in AUVELITY sales. The company also provided a business update highlighting the launch of AUVELITY for agitation associated with Alzheimer’s …

Axsome Therapeutics (AXSM) Could Be 25% Undervalued As CNS Pipeline Hopes Build

Axsome Therapeutics (AXSM) is considered 25% undervalued with a fair value of $282.51, despite a recent 9% stock decline. The valuation is driven by its expanding CNS portfolio, late-stage clinical programs, and projected rapid revenue growth and margin improvements. However, the company faces risks …

How Axsome Therapeutics Inc. (AXSM) Affects Rotational Strategy Timing

Axsome Therapeutics Inc. (AXSM) is analyzed through institutional trading strategies by Stock Traders Daily. The report identifies weak near and mid-term sentiment but a strong long-term outlook for AXSM, highlighting specific entry, target, and stop-loss points for position, momentum, and risk-hedging strategies. AI-generated signals …

AXSOME THERAPEUTICS Q2 2026 Earnings Preview: Recent $AXSM Insider Trading, Hedge Fund Activity, and More

AXSOME THERAPEUTICS ($AXSM) is set to release its Q2 2026 earnings on August 10th, with analysts projecting revenues of $225.45 million and an EPS of -$0.86. The article details recent insider trading activity, showing 16 sales and zero purchases over the last six months …

Axsome Therapeutics, Inc. $AXSM Shares Sold by Bank of America Corp DE

Bank of America Corp DE reduced its stake in Axsome Therapeutics by 3.2% in the first quarter, selling 19,942 shares and retaining 598,091 shares worth $101.1 million. Despite mixed analyst ratings, the company holds a "Moderate Buy" consensus with a $265.55 price target. Over …

Axsome therapeutics CEO Herriot Tabuteau sells $10.5m in shares

Axsome Therapeutics CEO Herriot Tabuteau sold approximately $10.5 million worth of common stock on August 5 and 6, 2026, following the exercise of stock options that were nearing their expiration date. These transactions were executed under a pre-approved 10b5-1 trading plan. Despite the sales, …

Axsome Therapeutics (AXSM) Stock Looks Near Fair Value Despite Premium Sales Pricing

Axsome Therapeutics (AXSM) stock appears to be priced near its fair value, despite its premium sales pricing, following a significant 5-year gain and a recent pullback. The company's P/S ratio of 15.3x is higher than industry averages but aligns closely with its estimated fair …

AXSM (AXSM) holder files to sell 4,660 shares via cashless option exercise

A holder of Axsome Therapeutics (AXSM) has filed a Form 144 to sell 4,660 common shares through a cashless option exercise, valued at approximately $979,205.80. These shares, acquired in 2017 as compensation via stock options, are intended for sale on or after August 6, …

Axsome Therapeutics (AXSM) insider plans 45,004-share cashless option sale

Axsome Therapeutics insider Herriot Tabuteau has filed a Form 144 indicating an intention to sell up to 45,004 shares of common stock through Goldman Sachs & Co. LLC, with an approximate sale date of August 5, 2026. The shares were originally acquired as compensation …

Axsome Therapeutics Inc (AXSM) News, Articles, Events & Latest Updates

This article provides a compilation of recent news, articles, and updates related to Axsome Therapeutics Inc (AXSM), focusing on its upcoming Q2 earnings, FDA approvals, and ongoing clinical trials. It also includes several Zacks reports placing AXSM on a "Strong Sell" list. Additionally, it …